<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00743119</url>
  </required_header>
  <id_info>
    <org_study_id>5603</org_study_id>
    <secondary_id>5P50DA009236</secondary_id>
    <nct_id>NCT00743119</nct_id>
  </id_info>
  <brief_title>Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers</brief_title>
  <official_title>Comparison of the Analgesic Effects of Dronabinol and Smoked Marijuana in Daily Marijuana Smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Research Foundation for Mental Hygiene, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The following study is designed to determine the analgesic efficacy of smoked marijuana (0,
      1.98, and 3.56% THC) and oral THC (0, 10, and 20 mg) in the Cold-Pressor Test (CPT), a
      laboratory model of pain which has predictive validity for clinical use of analgesics. Oral
      THC (dronabinol) is known to have a slower onset and longer duration of action compared with
      smoked marijuana. Therefore, the analgesic effects of oral THC is expected to peak later and
      last longer than effects produced by smoked marijuana.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Laboratory animal studies have demonstrated the analgesic effects of drugs which act on the
      cannabinoid system, however, these effects have et to be clearly elucidated in humans. To
      better understand the potential clinical application of cannabinoids for pain management, the
      following study is designed to determine the analgesic efficacy of smoked marijuana (3.56%
      THC) and oral THC (20 mg) in the Cold-Pressor Test (CPT), a laboratory model of pain which
      has predictive validity for clinical use of analgesics. Non-treatment seeking marijuana
      smokers will be recruited for a five-session study during which the analgesic, subjective,
      and physiologic effects of cannabinoids will be evaluated. Determining the efficacy of
      cannabinoids in an experimental model of pain will provide important endpoints (i.e., dose,
      route of administration, time course) or this effect to further investigate the potential
      role for clinical use of smoked marijuana and/or oral THC as analgesics.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Placebo-controlled, double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Tolerance</measure>
    <time_frame>Within each session lasting approximately 5 minutes, for a total of five sessions</time_frame>
    <description>Change in pain tolerance from baseline (in seconds) as a function of drug condition. The cold pressor test was administered during each session to examine changes in pain threshold (how many seconds it takes for a participant to begin feeling pain after cold water immersion).</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Pain Threshold</condition>
  <condition>Mood</condition>
  <arm_group>
    <arm_group_label>Placebo + inactive marijuana (0% THC)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo capsules and smoked inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dronabinol 10 mg + Marijuana (0% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received low dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dronabinol 20 mg + Marijuana (0% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received High dose Dronabinol + inactive marijuana (0% THC) on 1 of 5 outpatient sessions in randomized order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Marijuana (1.98% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received placebo + low THC marijuana (1.98% THC) on 1 of 5 outpatient sessions in randomized order.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Marijuana (3.56% THC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received placebo + smoked high THC marijuana (3.56 % THC) on 1 of 5 outpatient sessions in randomized order.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsules</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo + inactive marijuana (0% THC)</arm_group_label>
    <arm_group_label>Placebo + Marijuana (1.98% THC)</arm_group_label>
    <arm_group_label>Placebo + Marijuana (3.56% THC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inactive marijuana (0% THC)</intervention_name>
    <description>Inactive marijuana cigarettes (0% THC) provided by NIDA</description>
    <arm_group_label>Placebo + inactive marijuana (0% THC)</arm_group_label>
    <arm_group_label>Dronabinol 10 mg + Marijuana (0% THC)</arm_group_label>
    <arm_group_label>Dronabinol 20 mg + Marijuana (0% THC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low dose Dronabinol</intervention_name>
    <description>Dronabinol 10mg</description>
    <arm_group_label>Dronabinol 10 mg + Marijuana (0% THC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High dose Dronabinol</intervention_name>
    <description>Dronabinol 20mg</description>
    <arm_group_label>Dronabinol 20 mg + Marijuana (0% THC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Low THC marijuana</intervention_name>
    <description>marijuana cigarettes (1.98% THC) provided by NIDA</description>
    <arm_group_label>Placebo + Marijuana (1.98% THC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High THC marijuana</intervention_name>
    <description>Marijuana cigarettes (3.56% THC) provided by NIDA</description>
    <arm_group_label>Placebo + Marijuana (3.56% THC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults between the ages of 21-45

          -  Current marijuana use

          -  Able to perform study procedures

          -  Women practicing an effective form of birth control

        Exclusion Criteria:

          -  Female subjects who are currently pregnant or breastfeeding

          -  Current,repeated illicit drug use other than marijuana

          -  Presence of significant medical illness

          -  History of heart disease

          -  Request for drug treatment

          -  Current parole or probation

          -  Recent history of significant violent behavior
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margaret Haney, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cooper ZD, Comer SD, Haney M. Comparison of the analgesic effects of dronabinol and smoked marijuana in daily marijuana smokers. Neuropsychopharmacology. 2013 Sep;38(10):1984-92. doi: 10.1038/npp.2013.97. Epub 2013 Apr 22.</citation>
    <PMID>23609132</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2008</study_first_submitted>
  <study_first_submitted_qc>August 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2008</study_first_posted>
  <results_first_submitted>October 20, 2016</results_first_submitted>
  <results_first_submitted_qc>November 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 11, 2017</results_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral thc</keyword>
  <keyword>cannabis</keyword>
  <keyword>pain</keyword>
  <keyword>analgesic effects</keyword>
  <keyword>dronabinol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marijuana Abuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Dronabinol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Thirty-four participants were enrolled, and 30 completed. A total of 30 participants completed all 5 treatment combinations in randomized order.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo/Dronabinol + Marijuana</title>
          <description>During each session, one capsule containing placebo or dronabinol (10 mg or 20 mg) was administered to the participant 45 min before marijuana was smoked (0, 1.98, or 3.56% THC marijuana). Only one active dose of marijuana or dronabinol was administered within a session. A within-subject design was used in which all participants received all strengths of dronabinol and marijuana. The order was randomized.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>unreliable</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Number of Baseline Participants</title>
          <description>34 participants were enrolled, but only 30 participants completed. Out of the additional 4 volunteers, 1 discontinued for personal reasons and three were unreliable.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Tolerance</title>
        <description>Change in pain tolerance from baseline (in seconds) as a function of drug condition. The cold pressor test was administered during each session to examine changes in pain threshold (how many seconds it takes for a participant to begin feeling pain after cold water immersion).</description>
        <time_frame>Within each session lasting approximately 5 minutes, for a total of five sessions</time_frame>
        <population>All participants who completed the study (N=30) were included in the final analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>High Dose Dronabinol + Inactive Marijuana</title>
            <description>Dronabinol 20 mg + inactive marijuana (0%THC)</description>
          </group>
          <group group_id="O2">
            <title>Low Dose Dronabinol + Inactive Marijuana</title>
            <description>10mg Dronabinol + inactive Marijuana (0% THC)</description>
          </group>
          <group group_id="O3">
            <title>Placebo + Low THC Marijuana</title>
            <description>Placebo + Marijuana (1.98% THC)</description>
          </group>
          <group group_id="O4">
            <title>Placebo + High THC Marijuana</title>
            <description>Placebo + high dose Marijuana (3.56% THC)</description>
          </group>
          <group group_id="O5">
            <title>Placebo + Inactive Marijuana 0% THC</title>
            <description>Placebo + inactive marijuana (0% THC)</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Tolerance</title>
          <description>Change in pain tolerance from baseline (in seconds) as a function of drug condition. The cold pressor test was administered during each session to examine changes in pain threshold (how many seconds it takes for a participant to begin feeling pain after cold water immersion).</description>
          <population>All participants who completed the study (N=30) were included in the final analysis.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="30"/>
                <count group_id="O4" value="30"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="4.4"/>
                    <measurement group_id="O2" value="2.8" spread="2.9"/>
                    <measurement group_id="O3" value="4.9" spread="3.4"/>
                    <measurement group_id="O4" value="1.5" spread="1.4"/>
                    <measurement group_id="O5" value="1.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were documented pre- and post-treatment and 1 week after completion of the entire study.</time_frame>
      <desc>Research staff routinely asked participants to report any adverse events occurring during study sessions and during outpatient washout periods.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo + Marijuana (0% THC)</title>
          <description>Adverse events recorded during Placebo (PBO) + Marijuana (0% THC) treatment</description>
        </group>
        <group group_id="E2">
          <title>Dronabinol 10 mg + Marijuana (0% THC)</title>
          <description>Adverse events recorded during Dronabinol 10 mg + Marijuana (0% THC) treatment</description>
        </group>
        <group group_id="E3">
          <title>Dronabinol 20mg + Marijuana (0% THC)</title>
          <description>Adverse events recorded during Dronabinol 20mg + Marijuana (0% THC) treatment</description>
        </group>
        <group group_id="E4">
          <title>Placebo + Marijuana (1.98% THC)</title>
          <description>Adverse events recorded during placebo + Marijuana (1.98% THC) treatment</description>
        </group>
        <group group_id="E5">
          <title>Placebo + Marijuana (3.56% THC)</title>
          <description>Adverse events recorded during Placebo + Marijuana (3.56% THC) treatment</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="34"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ziva Cooper</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646-774-6129</phone>
      <email>zc2160@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

